evaluating the benefits of lenvatinib and paclitaxel in recurrent gynecologic cancers
Published 5 years ago • 206 plays • Length 1:08Download video MP4
Download video MP3
Similar videos
-
0:52
investigating toxicities with lenvatinib plus paclitaxel in ovarian and endometrial cancers
-
1:19
relacorilant nab-paclitaxel in recurrent, platinum-resistant ovarian cancer
-
0:55
dr. backes on safety profile of lenvatinib and weekly paclitaxel in endometrial cancer
-
1:14
dr. backes on rationale for lenvatinib and weekly paclitaxel in endometrial cancer
-
1:55
rationale for chemotherapy plus veliparib in frontline treatment of ovarian cancers
-
4:02
#esmo19: lenvatinib (len) and pembrolizumab (pembro) in advanced endometrial cancer
-
1:00
rationalizing use of pembrolizumab/bevacizumab in recurrent ovarian cancer
-
2:05
dr. leath on clinical outcomes and quality of life in ovarian cancer
-
1:31
early data presented for lenvatinib and pembrolizumab in thyroid cancer
-
1:10
rebastinib and paclitaxel for advanced/metastatic ovarian cancer
-
57:40
immunotherapy in endometrial cancer: expanding horizons
-
5:04
reviewing lenvatinib data for treatment in mhcc
-
2:25
results of niraparib/bevacizumab combo in platinum-sensitive recurrent ovarian cancer
-
1:01:26
practical perspectives on rapid change in endometrial and cervical cancer management
-
1:17
dr. matulonis on the use of immunotherapy in recurrent ovarian cancer
-
5:19
abiraterone in patients with recurrent epithelial ovarian cancer
-
6:34
bevacizumab’s value in recurrent ovarian cancer
-
2:16
dr. matulonis discusses mirvetuximab soravtansine plus pembrolizumab in ovarian cancer
-
1:30:08
chemotherapy & immunotherapy options for genitourinary malignancies: a primer for urologists & apps